#1 Clinical Trials Search in Europe

Exagamglogene Autotemcel

Exagamglogene autotemcel, also known as exa-cel or CTX001, is an innovative gene therapy being studied in clinical trials for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This therapy uses CRISPR-Cas9 gene editing technology to modify a patient’s own blood stem cells, aiming to increase the production of fetal hemoglobin and potentially reduce or eliminate the need for blood transfusions and other disease-related complications.

Table of Contents

What is EXAGAMGLOGENE AUTOTEMCEL?

EXAGAMGLOGENE AUTOTEMCEL, also known as Casgevy or exa-cel, is a groundbreaking gene therapy developed to treat severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)[1]. This innovative treatment uses a patient’s own stem cells, which are modified using CRISPR-Cas9 gene editing technology to address the underlying genetic cause of these blood disorders[1].

How Does It Work?

Exa-cel works by using CRISPR-Cas9 gene editing to modify a specific genetic region called the BCL11A erythroid enhancer. This modification disrupts the BCL11A gene, which normally suppresses the production of fetal hemoglobin (HbF)[2]. By “turning off” this suppressor, the therapy allows the body to produce higher levels of HbF, which can effectively compensate for the defective adult hemoglobin in patients with SCD and TDT[2].

What Conditions Does It Treat?

EXAGAMGLOGENE AUTOTEMCEL is designed to treat two severe inherited blood disorders:

  • Severe Sickle Cell Disease (SCD): A condition where abnormal hemoglobin causes red blood cells to become crescent-shaped, leading to painful crises, organ damage, and other complications[3].
  • Transfusion-Dependent Beta-Thalassemia (TDT): A disorder characterized by reduced or absent production of beta-globin, a component of hemoglobin, resulting in severe anemia and lifelong dependence on blood transfusions[4].

How is It Administered?

The treatment process involves several steps:

  1. Collection of the patient’s own hematopoietic stem cells (cells that can develop into all types of blood cells)
  2. Modification of these cells in a laboratory using CRISPR-Cas9 technology
  3. Chemotherapy to prepare the patient’s body (known as conditioning)
  4. Infusion of the modified cells back into the patient’s bloodstream

This one-time treatment is administered intravenously as a dispersion for infusion[5].

How Effective Is It?

Clinical trials have shown promising results for both SCD and TDT patients:

  • For SCD: A significant proportion of patients achieved freedom from severe vaso-occlusive crises (painful episodes) for at least 12 consecutive months after treatment[2].
  • For TDT: Many patients achieved transfusion independence, maintaining adequate hemoglobin levels without the need for blood transfusions for at least 12 consecutive months[4].

The therapy has demonstrated the ability to significantly increase fetal hemoglobin (HbF) levels and total hemoglobin concentrations in treated patients[5].

Safety Information

As with any advanced therapy, safety is a crucial consideration. Common side effects may include those related to the cell collection process and the chemotherapy used for conditioning. Long-term follow-up studies are ongoing to monitor for any delayed effects[1].

Patients are typically monitored for:

  • Successful neutrophil and platelet engraftment
  • Adverse events
  • Changes in clinical laboratory values
  • Transplant-related mortality

Ongoing Research

Multiple clinical trials are currently underway to further evaluate the safety and efficacy of EXAGAMGLOGENE AUTOTEMCEL in both adult and pediatric populations. These studies are assessing various outcomes, including:

  • Long-term effectiveness in reducing disease symptoms and complications
  • Quality of life improvements
  • Durability of treatment effects
  • Potential long-term side effects

Researchers are also studying the therapy’s impact on markers of disease severity, such as hemolysis (breakdown of red blood cells) in SCD and iron overload in TDT[6].

Who Is Eligible for This Treatment?

Eligibility criteria for EXAGAMGLOGENE AUTOTEMCEL treatment typically include:

  • Confirmed diagnosis of severe SCD or TDT
  • For SCD: History of recurrent severe vaso-occlusive crises
  • For TDT: Regular blood transfusion dependency
  • Eligibility for autologous stem cell transplant
  • No available matched sibling donor for traditional stem cell transplant
  • No active, severe infections
  • Adequate organ function to undergo the procedure

Specific eligibility may vary depending on individual clinical circumstances and ongoing trial protocols[3].

Conclusion

EXAGAMGLOGENE AUTOTEMCEL represents a significant advancement in the treatment of severe sickle cell disease and transfusion-dependent beta-thalassemia. By addressing the genetic root of these disorders, this therapy offers the potential for long-term relief from symptoms and complications, potentially freeing patients from lifelong medical interventions like frequent blood transfusions or pain management.

As research continues and more data becomes available, this innovative treatment may transform the lives of many individuals affected by these challenging blood disorders. Patients interested in this therapy should consult with their hematologists to discuss eligibility and potential benefits in their specific cases.

Aspect Details
Therapy Name Exagamglogene autotemcel (exa-cel, CTX001)
Type of Treatment Gene therapy using CRISPR-Cas9 modified autologous hematopoietic stem cells
Target Conditions Severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT)
Administration Single intravenous infusion
Primary Objectives Evaluate safety and efficacy in reducing disease-related events and transfusion dependency
Key Endpoints Reduction in vaso-occlusive crises (SCD), transfusion independence (TDT), fetal hemoglobin levels, safety assessments
Trial Phases Phase 1/2/3 studies ongoing
Patient Population Adolescents and adults with severe SCD or TDT
Follow-up Duration Up to 15 years post-infusion in some studies

FAQ

  • What is exagamglogene autotemcel? Exagamglogene autotemcel is a gene therapy that uses CRISPR-Cas9 technology to edit a patient's own blood stem cells. It aims to increase the production of fetal hemoglobin to treat severe sickle cell disease and transfusion-dependent beta-thalassemia.
  • How is exagamglogene autotemcel administered? Exagamglogene autotemcel is administered as a single intravenous infusion of the patient's own modified blood stem cells. Before the infusion, patients undergo a process to collect their stem cells, which are then edited and prepared for reinfusion.
  • What are the main goals of the clinical trials for exagamglogene autotemcel? The main goals are to evaluate the safety and efficacy of the therapy. This includes assessing its ability to reduce or eliminate the need for blood transfusions, decrease the frequency of pain crises in sickle cell disease, and improve overall quality of life for patients.
  • Who is eligible for these clinical trials? Eligibility varies by trial, but generally includes patients with severe sickle cell disease or transfusion-dependent beta-thalassemia. Specific criteria may include a history of frequent pain crises or high transfusion requirements, and being eligible for stem cell transplantation.
  • What are some potential benefits and risks of this therapy? Potential benefits include reduced need for blood transfusions, fewer pain crises, and improved quality of life. Risks may include side effects related to the stem cell collection and infusion process, as well as potential long-term effects of genetic modification. The trials are designed to carefully monitor both short-term and long-term outcomes.

Ongoing Clinical Trials on Exagamglogene Autotemcel

  • Study on the Safety and Effectiveness of CTX001 for Children with Severe Sickle Cell Disease Using Exagamglogene Autotemcel, Busulfan, and Plerixafor

    Recruiting

    3 1 1 1
    Investigated drugs:
    Germany Italy

  • Study on the Safety and Effectiveness of CTX001 for Children with Transfusion-Dependent Beta-Thalassemia Using Exagamglogene Autotemcel and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Germany Italy

  • Long-term Safety Study of Exagamglogene Autotemcel for Patients with Sickle Cell Disease or Transfusion-Dependent Thalassemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy

  • Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Effectiveness and Safety of Exa-cel for Adolescents and Adults with Severe Sickle Cell Disease

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

  • Study of Exagamglogene Autotemcel (CTX001) for Treatment of Severe Sickle Cell Disease Using Modified Stem Cells

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy

  • Study on the Safety and Effectiveness of CRISPR-Cas9 Modified Stem Cells for Patients with Transfusion-Dependent Beta-Thalassemia Using Exagamglogene Autotemcel

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Exagamglogene autotemcel: A gene therapy that uses CRISPR-Cas9 technology to edit a patient's own blood stem cells, aiming to increase fetal hemoglobin production for treating sickle cell disease and beta-thalassemia.
  • CRISPR-Cas9: A gene-editing technology that allows for precise modifications to DNA, used in this therapy to target and modify specific genes related to hemoglobin production.
  • Sickle Cell Disease (SCD): A group of inherited red blood cell disorders where abnormal hemoglobin causes red blood cells to become sickle-shaped, leading to pain, organ damage, and other complications.
  • Transfusion-Dependent Beta-Thalassemia (TDT): A severe form of beta-thalassemia where patients require regular blood transfusions to survive due to their inability to produce sufficient normal hemoglobin.
  • Fetal Hemoglobin (HbF): A type of hemoglobin normally produced during fetal development. Increasing its production in adults may help alleviate symptoms of SCD and TDT.
  • Hematopoietic Stem Cells: Blood-forming stem cells found in bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets.
  • Vaso-Occlusive Crisis (VOC): A common and painful complication of sickle cell disease where sickled red blood cells block small blood vessels, causing pain and potential organ damage.
  • Autologous: Referring to cells or tissues obtained from the same individual. In this therapy, the patient's own stem cells are modified and then reinfused.
  • Engraftment: The process by which transplanted stem cells start to grow and produce new blood cells in the recipient's body.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body. Abnormal hemoglobin is the cause of sickle cell disease and beta-thalassemia.

References

  1. http://clinicaltrials.eu/trial/2024-512654-19-00
  2. http://clinicaltrials.eu/trial/2024-516067-83-00
  3. http://clinicaltrials.eu/trial/2023-503247-34-00
  4. http://clinicaltrials.eu/trial/2024-516894-57-00
  5. http://clinicaltrials.eu/trial/2024-514641-12-00
  6. http://clinicaltrials.eu/trial/2024-513978-22-00